[Enoxacin for type III A prostatitis: a clinical observation]

Chronic prostatitis remains a poorly understood condition with limited effective treatment options. Prior research has shown that type III A prostatitis, a non-bacterial form, is particularly challenging to manage. No prior work had resolved the best antibiotic for this condition. Established knowledge includes the use of quinolones, but their specific efficacy for type III A is unclear. This gap motivated a need for targeted clinical evaluation. The NIH-CPSI score is a standard tool, but its use with enoxacin had not been established. Prior studies lacked follow-up data, making long-term outcomes uncertain. This paper contributes by evaluating enoxacin specifically in a type III A cohort. The study provides a novel approach to a persistent clinical challenge.

This study aimed to evaluate enoxacin's effectiveness in treating type III A prostatitis. The specific problem is the lack of reliable therapeutic options for this condition. The motivation stems from clinical uncertainty about antibiotic efficacy in non-bacterial prostatitis. Researchers wanted to determine if enoxacin could offer a safe and effective solution. The NIH-CPSI score was selected as a validated outcome measure. The study design included a standardized treatment protocol. Follow-up data was essential to assess long-term outcomes. This approach addresses a critical need in urological care.

The study involved 198 male outpatients diagnosed with type III A prostatitis. Participants received enoxacin injection for one week followed by oral administration for two weeks. NIH-CPSI scores were recorded before and after treatment. Expressed prostatic secretions (EPS) were analyzed for changes. Gastrointestinal and skin reactions were monitored as adverse effects. Data collection included both subjective symptom scores and objective EPS results. The treatment protocol was consistent across all participants. Outcomes were categorized as cure, improvement, or ineffectiveness.

The total effectiveness rate was 86.4% among participants. Cure was achieved in 8.6% of cases (17/198). Remarkable effectiveness occurred in 58.1% (115/198). Improvement was observed in 19.7% (39/198). Ineffectiveness was reported in 13.6% (27/198). Adverse effects were minimal, with 8.1% (16/198) reporting transient gastrointestinal discomfort or skin itching. NIH-CPSI scores showed significant improvement post-treatment. EPS analysis confirmed symptom-related changes. These results suggest enoxacin is well-tolerated and effective.

The authors propose that enoxacin is a desirable treatment option for type III A prostatitis. The study demonstrates its efficacy with a high total effectiveness rate. Minimal adverse effects were reported, supporting its safety profile. The NIH-CPSI score improvements suggest symptom relief. EPS changes indicate biological response to treatment. The authors suggest enoxacin could be a preferred choice for this condition. No prior work had established such a clear outcome. These findings may guide future clinical decisions.